MedTrace Logo

Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department

NCT06961058 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 528

Last updated 2025-10-22

No results posted yet for this study

Summary

Main study objective: compare long-term buprenorphine treatment outcomes for patients who start buprenorphine for opioid use disorder (OUD) in the emergency department and are then referred to get outpatient buprenorphine treatment either via telehealth or at an in-person clinic.

Researchers will:

Compare rates of establishing outpatient OUD treatment, how long patients stay on buprenorphine, and patients' experience with care to determine whether patient experiences and outcomes are better for patients referred to telehealth treatment versus patients patients referred to in-person treatment after they leave the emergency department.

Participants will:

Be recruited from 3 different hospital emergency departments.

Answer questionnaires at baseline and then 1, 3, 6, and 9 months after their initial emergency department visit.

Conditions

Interventions

OTHER

referral to telehealth treatment

the intervention tested will be referral to get outpatient treatment via telehealth. Participants in the telehealth arm will receive the intervention.

OTHER

referral to in person treatment

participants in the in person arm will be referred to in person OUD treatment after they leave the ED

Sponsors & Collaborators

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Aimee Moulin, MD MAS · University of California, Davis

  • Stephen G Henry, MD MSc · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-03
Primary Completion
2029-06-01
Completion
2029-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06961058 on ClinicalTrials.gov